What is HC Wainwright’s Estimate for FBIO Q4 Earnings?

Fortress Biotech, Inc. (NASDAQ:FBIO) – Analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Fortress Biotech in a research note issued on Monday, November 18th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($0.83) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Fortress Biotech’s current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Fortress Biotech’s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at ($0.46) EPS.

Separately, StockNews.com downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.67.

Fortress Biotech Trading Down 1.3 %

FBIO opened at $1.57 on Wednesday. The company’s 50 day moving average is $1.69 and its 200-day moving average is $1.83. The company has a market cap of $43.33 million, a P/E ratio of -0.51 and a beta of 1.75. Fortress Biotech has a 1-year low of $1.36 and a 1-year high of $4.43.

Insiders Place Their Bets

In related news, CEO Lindsay A. Md Rosenwald bought 763,359 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average price of $1.84 per share, with a total value of $1,404,580.56. Following the completion of the transaction, the chief executive officer now directly owns 3,657,264 shares in the company, valued at approximately $6,729,365.76. This represents a 26.38 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On Fortress Biotech

A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Fortress Biotech in the 1st quarter worth approximately $31,000. Integrated Wealth Concepts LLC lifted its holdings in Fortress Biotech by 68.2% during the third quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 18,700 shares during the period. Atria Investments Inc boosted its position in Fortress Biotech by 58.4% in the third quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 26,351 shares during the last quarter. 180 Wealth Advisors LLC bought a new position in Fortress Biotech in the 2nd quarter valued at $107,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of Fortress Biotech during the 2nd quarter valued at $207,000. 96.51% of the stock is owned by institutional investors.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.